Ignite Creation Date:
2024-05-06 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 2:30 PM
Study NCT ID:
NCT05342389
Status:
UNKNOWN
Last Update Posted:
2022-04-22
First Post:
2022-04-16
Brief Title:
Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer
Sponsor:
Sixth Affiliated Hospital Sun Yat-sen University
Organization:
Sixth Affiliated Hospital Sun Yat-sen University
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-05-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2023-05-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-11-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-04-16
First Submit QC Date:
April 16 2022
Study First Post Date:
2022-04-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-04-16
Last Update Post Date:
2022-04-22
Last Update Post Date Type:
ACTUAL